Fresenius Medical Care AG & Co KGaA
XETRA:FME
Fresenius Medical Care AG & Co KGaA
Fresenius Medical Care AG & Co KGaA, articulating a saga of innovation and resilience, stands at the global forefront of dialysis care. Born out of a convergence of medical expertise and humanitarian ambition, the company caters to individuals battling chronic kidney disease. It operates through an intricate network of dialysis clinics and manufacturing facilities spread across continents. These clinics are the lifeline for many, transforming what is essentially a life-threatening condition into a manageable routine. The process is remarkable: patients are connected to dialysis machines, many of which are crafted by Fresenius itself. These machines emulate the essential functions of kidneys by filtering and purifying blood, a process pivotal for sustaining life in those with kidney failure.
The dual avenues of Fresenius Medical Care's revenue generation create a unique synergy driving the company's success. One arm of its business involves providing essential dialysis treatments through its expansive clinic network, offering healthcare services directly to patients worldwide. The other arm engages in the production and sale of dialysis products, encompassing everything from dialysis machines to a wide range of associated medical supplies. Hospitals and other healthcare providers across the globe depend on these products, further broadening Fresenius's impact and revenue streams. This symbiotic integration of services and products not only reinforces its market leadership but also aligns the company's growth with advancements in patient outcomes and healthcare technology.
Fresenius Medical Care AG & Co KGaA, articulating a saga of innovation and resilience, stands at the global forefront of dialysis care. Born out of a convergence of medical expertise and humanitarian ambition, the company caters to individuals battling chronic kidney disease. It operates through an intricate network of dialysis clinics and manufacturing facilities spread across continents. These clinics are the lifeline for many, transforming what is essentially a life-threatening condition into a manageable routine. The process is remarkable: patients are connected to dialysis machines, many of which are crafted by Fresenius itself. These machines emulate the essential functions of kidneys by filtering and purifying blood, a process pivotal for sustaining life in those with kidney failure.
The dual avenues of Fresenius Medical Care's revenue generation create a unique synergy driving the company's success. One arm of its business involves providing essential dialysis treatments through its expansive clinic network, offering healthcare services directly to patients worldwide. The other arm engages in the production and sale of dialysis products, encompassing everything from dialysis machines to a wide range of associated medical supplies. Hospitals and other healthcare providers across the globe depend on these products, further broadening Fresenius's impact and revenue streams. This symbiotic integration of services and products not only reinforces its market leadership but also aligns the company's growth with advancements in patient outcomes and healthcare technology.
Profitability: Fresenius Medical Care delivered a strong step-up in profitability for 2025, achieving the upper end of its outlook, with group margin reaching 11.3% for the year and an exceptional 13.9% in Q4.
Revenue & Earnings: Organic revenue grew 8% in Q4, with full-year operating income up 27%, hitting the top end of guidance. Q4 earnings grew 53%, driven by operational improvements and regulatory benefits.
TDAPA & Regulatory: Significant temporary benefit from TDAPA regulations and phosphate binders (EUR 220 million in 2025) boosted results but is expected to phase out starting in 2026, creating a meaningful headwind.
Shareholder Returns: The company completed the first tranche of a EUR 1 billion share buyback (EUR 586 million in 2025), plans to propose a EUR 1.49 dividend (up 3%), and reduced net leverage to 2.5x.
Outlook 2026: Management expects 2026 to be a transition year, with broadly flat revenue and operating income due to high prior-year base and regulatory headwinds, but aims to maintain enhanced profitability.
Strategic Initiatives: The FME25+ transformation program exceeded targets, with EUR 804 million sustainable savings to date and plans to reach EUR 1.2 billion by 2027.
US Clinic Expansion: The large-scale rollout of the 5008X CAREsystem in US clinics is underway, set to replace 20% of the installed base in 2026 and improve patient outcomes in future years.
China Headwinds: Regulatory changes in China impacted Care Enablement, with a EUR 50 million EBIT drag in 2025 and continued, though smaller, impact expected in 2026.
